These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34090142)

  • 1. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
    Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
    Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study.
    Hadoux J; Walter T; Kanaan C; Hescot S; Hautefeuille V; Perrier M; Tauveron I; Laboureau S; Do Cao C; Petorin C; Blanchet O; Faron M; Leteurtre E; Rousselet MC; Joubert Zakeyh J; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Lombard-Bohas C; Ducreux M; Scoazec JY; Baudin E; ;
    Endocr Relat Cancer; 2022 Oct; 29(10):569-580. PubMed ID: 35920609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
    Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
    Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
    Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Iwasaki T; Takenaga N; Kasahara Y; Ouchi K; Shirota H; Takahashi M; Ishioka C
    Oncology; 2024; 102(5):359-367. PubMed ID: 37903486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
    Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
    J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
    Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
    Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
    Hadoux J; Afchain P; Walter T; Tougeron D; Hautefeuille V; Monterymard C; Lorgis V; Thuillier F; Baudin E; Scoazec JY; Lepage C; Desgrippes R
    Dig Liver Dis; 2021 Jul; 53(7):824-829. PubMed ID: 33994125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
    Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
    Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
    Yamaguchi T; Machida N; Morizane C; Kasuga A; Takahashi H; Sudo K; Nishina T; Tobimatsu K; Ishido K; Furuse J; Boku N; Okusaka T
    Cancer Sci; 2014 Sep; 105(9):1176-81. PubMed ID: 24975505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
    Rinke A; Gress TM
    Digestion; 2017; 95(2):109-114. PubMed ID: 28161703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
    Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
    Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma.
    McGarrah PW; Leventakos K; Hobday TJ; Molina JR; Finnes HD; Westin GF; Halfdanarson TR
    Pancreas; 2020 Apr; 49(4):529-533. PubMed ID: 32282766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy in Resected Neuroendocrine Carcinomas of the Digestive Tract: A National Study from the French Group of Endocrine Tumours.
    Pellat A; Walter T; Augustin J; Hautefeuille V; Hentic O; Do Cao C; Lievre A; Coriat R; Hammel P; Dubreuil O; Cohen R; Couvelard A; André T; Svrcek M; Baudin E; Afchain P
    Neuroendocrinology; 2020; 110(5):404-412. PubMed ID: 31430756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.
    Bongiovanni A; Liverani C; Pusceddu S; Leo S; Di Meglio G; Tamberi S; Santini D; Gelsomino F; Pucci F; Berardi R; Lolli I; Bergamo F; Ricci S; Foca F; Severi S; Ibrahim T;
    BMJ Open; 2020 Jul; 10(7):e034393. PubMed ID: 32690499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine Carcinoma of Gall Bladder: A Series of 19 Cases with Review of Literature.
    Kamboj M; Gandhi JS; Gupta G; Sharma A; Pasricha S; Mehta A; Chandragouda D; Sinha R
    J Gastrointest Cancer; 2015 Dec; 46(4):356-64. PubMed ID: 26208508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
    Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
    Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy.
    Honma Y; Nagashima K; Hirano H; Shoji H; Iwasa S; Takashima A; Okita N; Kato K; Boku N; Murakami N; Inaba K; Ito Y; Itami J; Kanamori J; Oguma J; Daiko H
    Cancer Med; 2020 Jan; 9(2):595-604. PubMed ID: 31794158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
    Lamarca A; Frizziero M; Barriuso J; McNamara MG; Hubner RA; Valle JW
    Clin Transl Oncol; 2019 Jul; 21(7):950-953. PubMed ID: 30506132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rb Loss and
    Hijioka S; Hosoda W; Matsuo K; Ueno M; Furukawa M; Yoshitomi H; Kobayashi N; Ikeda M; Ito T; Nakamori S; Ishii H; Kodama Y; Morizane C; Okusaka T; Yanagimoto H; Notohara K; Taguchi H; Kitano M; Yane K; Maguchi H; Tsuchiya Y; Komoto I; Tanaka H; Tsuji A; Hashigo S; Kawaguchi Y; Mine T; Kanno A; Murohisa G; Miyabe K; Takagi T; Matayoshi N; Yoshida T; Hara K; Imamura M; Furuse J; Yatabe Y; Mizuno N
    Clin Cancer Res; 2017 Aug; 23(16):4625-4632. PubMed ID: 28455360
    [No Abstract]   [Full Text] [Related]  

  • 20. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.